Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with… Ended

2023-508697-28-00 Frontotemporal Dementia (FTD) 7 2024-11-13
A Phase 2 Study of an Anti-MTBR Tau Monoclonal Antibody in Participants with Early Alzheimer’s Disease Ended

2023-504840-32-00 Early Alzheimer’s Disease 4 2024-11-08
Phase I/II Safety and Tolerability Study of striatal administration of AB-1001 in adult subjects with Early Manifest Huntington's Disease (H… Ended

2024-510895-18-00 Huntington's disease 7 2024-11-07
OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADUL… Ended

2023-505832-36-01 Type C Niemann-Pick Disease 4 2024-11-07
ALS phase II study of NX210c (SEALS) Ended

2023-508895-13-00 Amyotrophic Lateral Sclerosis (ALS) 4 2024-10-25
A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso… Ended

2024-511222-30-00 Multiple System Atrophy 4 2024-10-22
EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS Ended

2023-507541-29-00 Multiple sclerosis 4 2024-10-01
A study to check the effect of satralizumab in children and adolescents living with Duchenne muscular dystrophy, to check if it is safe and … Ended

2024-512383-65-00 Duchenne Muscular Dystrophy (DMD) 4 2024-09-26
PROSPER: clinical Phase 2 study to test how safe and effective is a new medicine called FNP-223 to slow disease progression of progressive s… Ended

2023-510366-28-00 Progressive supranuclear palsy (PSP) 4 2024-09-25
Comparison of an inhaled sedation strategy with an intravenous sedation strategy in intensive care patients treated with invasive mechanical… Ended

2024-513530-37-00 Delirium 5 2024-08-09
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Multiple Sclerosis 6 2024-07-30
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of… Ended

2023-507363-20-00 Amyotrophic lateral sclerosis (ALS) 1 2024-07-12
ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended

2023-507325-42-00 Alzheimer Disease psychosis 4 2024-07-02
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… Ended

2023-509678-52-00 Alzheimer's disease 9 2024-06-27
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
MTR² Ended

2022-502790-42-00 Primary Central Nervous Lymphoma (PCNSL) 4 2024-06-24
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Relapsing multiple sclerosis 1 2024-05-15
Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trial Ended

2023-506795-27-00 Adrenomyeloneuropathy 10 2024-04-15
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi… Ended

2023-506301-20-00 Tuberous Sclerosis Complex (TSC) 9 2024-04-15
A study to see how well KarXT works and how well tolerated it is in participants with psychosis associated with Alzheimer’s disease. Ended

2023-504416-16-00 Psychosis Associated with Alzheimer’s Disease 5 2024-04-11
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Chronic migraine 5 2024-03-18
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Episodic Migraine 5 2024-03-18